为了进一步提高KRAS G12C突变患者的治疗效果，研究团队设计了一项临床试验。他们尝试将靶向药索托拉西布与传统化疗（卡铂和培美曲塞）相结合，用于治疗晚期非鳞状非小细胞肺癌患者。

KRAS mutations are found in 25-30% of all cases with non-squamous histology. The KRAS-G12C mutation, specifically, is identified in nearly one in seven patients. For decades KRAS was considered ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its ...

Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.